Nexvet to price its IPO of 4 million shares between $13.00 and $16.00

BofA Merrill Lynch and Cowen are joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Jan. 26 – Nexvet Biopharma plc will sell 4 million ordinary shares in its initial public offering with a greenshoe option of 600,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $73.6 million of stock.

The shares will be sold at a price expected to fall between $13.00 and $16.00 per share.

BofA Merrill Lynch and Cowen and Co. are the joint bookrunning managers. Piper Jaffray and JMP Securities are the co-managers.

Proceeds will be used for research, studies and regulatory compliance and to complete the development and manufacturing scale-up of products.

The clinical-stage biopharmaceutical company is based in Dublin. The company intends to list its stock on the Nasdaq stock exchange under the symbol “NVET.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.